Alembic Pharmaceuticals Limited

NSE APLLTD.NS

Alembic Pharmaceuticals Limited Free Cash Flow Yield on February 07, 2025: 2.85%

Alembic Pharmaceuticals Limited Free Cash Flow Yield is 2.85% on February 07, 2025, a 93.09% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Alembic Pharmaceuticals Limited 52-week high Free Cash Flow Yield is 2.87% on June 20, 2024, which is 0.84% above the current Free Cash Flow Yield.
Alembic Pharmaceuticals Limited 52-week low Free Cash Flow Yield is 1.33% on February 22, 2024, which is -53.19% below the current Free Cash Flow Yield.
Alembic Pharmaceuticals Limited average Free Cash Flow Yield for the last 52 weeks is 2.23%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NSE: APLLTD.NS

Alembic Pharmaceuticals Limited

CEO	Mr. Chirayu Ramanbhai Amin
IPO Date	Sept. 20, 2011
Location	India
Headquarters	Alembic Road
Employees	14,858
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, and anti-diabetic. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

Key trends

Past 5 years